<table border="0" cellpadding="1" cellspacing="1" id="i9cf65c4a-590e-4700-8ef4-7c674348ec58" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 17: Drug Interactions: Pharmacokinetic Parameters for Atazanavir in the Presence of Coadministered Drugs<sup>a</sup>
</caption>
<colgroup>
<col width="17%"></col>
<col width="18%"></col>
<col width="19%"></col>
<col width="15%"></col>
<col width="15%"></col>
<col width="16%"></col>
</colgroup>
<thead>
<tr valign="bottom">
<th align="center" rowspan="2" stylecode="Toprule Botrule" valign="middle">
<content stylecode="bold">Coadministered Drug</content>
</th>
<th align="center" rowspan="2" stylecode="Toprule Botrule" valign="middle">
<content stylecode="bold">Coadministered Drug<br/>Dose/Schedule</content>
</th>
<th align="center" rowspan="2" stylecode="Toprule Botrule" valign="middle">
<content stylecode="bold">REYATAZ<br/>Dose/Schedule</content>
</th>
<th align="center" colspan="3" rowspan="1" stylecode="Toprule">
<content stylecode="bold">Ratio (90% Confidence Interval) of Atazanavir Pharmacokinetic Parameters with/without
Coadministered Drug;<br/>No Effect = 1.00</content>
</th>
</tr>
<tr valign="bottom">
<th align="center" colspan="1" rowspan="1" stylecode="Botrule" valign="bottom">
<content stylecode="bold">C<sub>max</sub>
</content>
</th>
<th align="center" colspan="1" rowspan="1" stylecode="Botrule" valign="bottom">
<content stylecode="bold">AUC</content>
</th>
<th align="center" colspan="1" rowspan="1" stylecode="Botrule" valign="bottom">
<content stylecode="bold">C<sub>min</sub>
</content>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="6" rowspan="1" stylecode="Toprule">
<sup>a</sup> Data provided are under fed conditions unless otherwise noted.</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<sup>b</sup> All drugs were given under fasted conditions.</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<sup>c</sup> 400 mg ddI EC and REYATAZ were administered together with food on Days 8 and 19.</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<sup>d</sup> REYATAZ 300 mg plus ritonavir 100 mg once daily coadministered with famotidine 40
mg twice daily resulted in atazanavir geometric mean C<sub>max</sub> that was similar and AUC and C<sub>min</sub> values that were 1.79-
and 4.46-fold higher relative to REYATAZ 400 mg once daily alone.</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<sup>e</sup> Similar results were noted when famotidine 20 mg BID was administered 2 hours after and 10 hours before atazanavir 300 mg and ritonavir 100 mg plus tenofovir 300 mg.</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<sup>f</sup> Atazanavir/ritonavir/tenofovir was administered after a light meal.</td>
</tr>
<tr>
<td colspan="6">
<sup>g </sup>Study was conducted in HIV-infected individuals. </td>
</tr>
<tr>
<td colspan="6">
<sup>h </sup>Compared with atazanavir 400 mg historical data without nevirapine (n=13), the ratio of geometric means
(90% confidence intervals) for C<sub>max</sub>, AUC, and C<sub>min</sub> were 1.42 (0.98, 2.05), 1.64 (1.11, 2.42), and 1.25 (0.66, 2.36), respectively,
for atazanavir/ritonavir 300/100 mg; and 2.02 (1.42, 2.87), 2.28 (1.54, 3.38), and 1.80 (0.94, 3.45), respectively, for atazanavir/ritonavir 400/100 mg.</td>
</tr>
<tr>
<td colspan="6">
<sup>i </sup>Parallel group design; n=23 for atazanavir/ritonavir plus nevirapine, n=22 for atazanavir 300 mg/ritonavir
100 mg without nevirapine. Subjects were treated with nevirapine prior to study entry. </td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<sup>j </sup>Omeprazole 40 mg was administered on an empty stomach 2 hours before REYATAZ.</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<sup>k </sup>Omeprazole 20 mg was administered 30 minutes prior to a light meal in the morning and REYATAZ 300 mg plus ritonavir 100 mg in the evening after a light meal, separated by 12 hours from omeprazole.</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<sup>l</sup>  REYATAZ 300 mg plus ritonavir 100 mg once daily separated by 12 hours from omeprazole
20 mg daily resulted in increases in atazanavir geometric mean AUC (10%) and C<sub>min </sub>(2.4-fold), with a decrease in C<sub>max</sub> (29%)
relative to REYATAZ 400 mg once daily in the absence of omeprazole (study days 1−6).</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<sup>m</sup>  Omeprazole 20 mg was given 30 minutes prior to a light meal in the morning and REYATAZ
400 mg plus ritonavir 100 mg once daily after a light meal, 1 hour after omeprazole. Effects on atazanavir concentrations were similar when REYATAZ 400 mg plus ritonavir 100 mg was separated from omeprazole 20 mg by 12 hours.</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<sup>n</sup> REYATAZ 400 mg plus ritonavir 100 mg once daily administered with omeprazole 20 mg
once daily resulted in increases in atazanavir geometric mean AUC (32%) and C<sub>min</sub> (3.3-fold), with a decrease in C<sub>max</sub> (26%)
relative to REYATAZ 400 mg once daily in the absence of omeprazole (study days 1−6).</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<sup>o</sup> Compared with atazanavir 400 mg QD historical data, administration of atazanavir/ritonavir
300/100 mg QD increased the atazanavir geometric mean values of C<sub>max</sub>, AUC, and C<sub>min</sub> by 18%, 103%, and 671%, respectively. </td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">
<sup>p</sup> Note that similar results were observed in studies where administration of tenofovir
and REYATAZ was separated by 12 hours.</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1" stylecode="Botrule">
<sup>q</sup> Ratio of atazanavir plus ritonavir plus tenofovir to atazanavir plus ritonavir.
Atazanavir 300 mg plus ritonavir 100 mg results in higher atazanavir exposure than atazanavir 400 mg (see footnote <sup>o</sup>). The geometric
mean values of atazanavir pharmacokinetic parameters when coadministered with ritonavir and tenofovir were: C<sub>max</sub> = 3190 ng/mL, AUC
= 34459 ng•h/mL, and C<sub>min</sub> = 491 ng/mL. Study was conducted in HIV-infected individuals.</td>
</tr>
</tfoot>
<tbody>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">atenolol</td>
<td align="center" colspan="1" rowspan="1">50 mg QD, d 7−11 (n=19) and d 19−23</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, d 1−11 (n=19)</td>
<td align="center" colspan="1" rowspan="1">1.00<br/>(0.89, 1.12)</td>
<td align="center" colspan="1" rowspan="1">0.93<br/>(0.85, 1.01)</td>
<td align="center" colspan="1" rowspan="1">0.74<br/>(0.65, 0.86)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">clarithromycin</td>
<td align="center" colspan="1" rowspan="1">500 mg BID, d 7−10 (n=29) and d 18−21</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, d 1−10 (n=29)</td>
<td align="center" colspan="1" rowspan="1">1.06<br/>(0.93, 1.20)</td>
<td align="center" colspan="1" rowspan="1">1.28<br/>(1.16, 1.43)</td>
<td align="center" colspan="1" rowspan="1">1.91<br/>(1.66, 2.21)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">didanosine (ddI) (buffered tablets) plus stavudine (d4T)<sup>b</sup>
</td>
<td align="center" colspan="1" rowspan="1">ddI: 200 mg x 1 dose,<br/>d4T: 40 mg x 1 dose (n=31)</td>
<td align="center" colspan="1" rowspan="1">400 mg x 1 dose simultaneously with ddI and d4T (n=31)</td>
<td align="center" colspan="1" rowspan="1">0.11<br/>(0.06, 0.18)</td>
<td align="center" colspan="1" rowspan="1">0.13<br/>(0.08, 0.21)</td>
<td align="center" colspan="1" rowspan="1">0.16<br/>(0.10, 0.27)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">ddI: 200 mg x 1 dose,<br/>d4T: 40 mg x 1 dose (n=32)</td>
<td align="center" colspan="1" rowspan="1">400 mg x 1 dose 1 h after ddI + d4T (n=32)</td>
<td align="center" colspan="1" rowspan="1">1.12<br/>(0.67, 1.18)</td>
<td align="center" colspan="1" rowspan="1">1.03<br/>(0.64, 1.67)</td>
<td align="center" colspan="1" rowspan="1">1.03<br/>(0.61, 1.73)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">ddI (enteric-coated [EC] capsules)<sup>c</sup>
</td>
<td align="center" colspan="1" rowspan="1">400 mg d 8 (fed) (n=34) 400 mg d 19 (fed) (n=31)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, d 2−8 (n=34) 300 mg/ritonavir 100 mg QD, d 9−19 (n=31)</td>
<td align="center" colspan="1" rowspan="1">1.03<br/>(0.93, 1.14)<br/>1.04<br/>(1.01, 1.07)</td>
<td align="center" colspan="1" rowspan="1">0.99<br/>(0.91, 1.08)<br/>1.00<br/>(0.96, 1.03)</td>
<td align="center" colspan="1" rowspan="1">0.98<br/>(0.89, 1.08)<br/>0.87<br/>(0.82, 0.92)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">diltiazem</td>
<td align="center" colspan="1" rowspan="1">180 mg QD, d 7−11 (n=30) and d 19−23</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, d 1−11 (n=30)</td>
<td align="center" colspan="1" rowspan="1">1.04<br/>(0.96, 1.11)</td>
<td align="center" colspan="1" rowspan="1">1.00<br/>(0.95, 1.05)</td>
<td align="center" colspan="1" rowspan="1">0.98<br/>(0.90, 1.07)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">efavirenz</td>
<td align="center" colspan="1" rowspan="1">600 mg QD, d 7−20 (n=27)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, d 1−20 (n=27)</td>
<td align="center" colspan="1" rowspan="1">0.41<br/>(0.33, 0.51)</td>
<td align="center" colspan="1" rowspan="1">0.26<br/>(0.22, 0.32)</td>
<td align="center" colspan="1" rowspan="1">0.07<br/>(0.05, 0.10)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">600 mg QD, d 7−20 (n=13)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, d 1−6 (n=23) then 300 mg/ritonavir 100 mg QD, 2 h before efavirenz, d 7−20 (n=13)</td>
<td align="center" colspan="1" rowspan="1">1.14<br/>(0.83, 1.58)</td>
<td align="center" colspan="1" rowspan="1">1.39<br/>(1.02, 1.88)</td>
<td align="center" colspan="1" rowspan="1">1.48<br/>(1.24, 1.76)</td>
</tr>
<tr>
<td valign="top"> </td>
<td align="center" valign="top">600 mg QD, d 11–24 (pm) (n=14)</td>
<td align="center" valign="top">300 mg QD/ritonavir 100 mg QD, d 1–10 (pm) (n=22), then 400 mg QD/ritonavir 100 mg QD, d 11–24 (pm), (simultaneous with efavirenz) (n=14)</td>
<td align="center" valign="top">1.17<br/>(1.08, 1.27)</td>
<td align="center" valign="top">1.00<br/>(0.91, 1.10)</td>
<td align="center" valign="top">0.58<br/>(0.49, 0.69)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">famotidine</td>
<td align="center" colspan="1" rowspan="1">40 mg BID, d 7−12 (n=15)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, d 1−6 (n=45), d 7−12 (simultaneous administration) (n=15)</td>
<td align="center" colspan="1" rowspan="1">0.53<br/>(0.34, 0.82)</td>
<td align="center" colspan="1" rowspan="1">0.59<br/>(0.40, 0.87) </td>
<td align="center" colspan="1" rowspan="1">0.58<br/>(0.37, 0.89)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">40 mg BID, d 7−12 (n=14)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD (pm), d 1−6 (n=14), d 7−12 (10 h after, 2 h before famotidine) (n=14)</td>
<td align="center" colspan="1" rowspan="1">1.08<br/>(0.82, 1.41)</td>
<td align="center" colspan="1" rowspan="1">0.95<br/>(0.74, 1.21)</td>
<td align="center" colspan="1" rowspan="1">0.79<br/>(0.60, 1.04)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">40 mg BID, d 11−20 (n=14)<sup>d</sup>
</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD, d 1−10 (n=46), d 11−20<sup>d</sup> (simultaneous administration) (n=14)</td>
<td align="center" colspan="1" rowspan="1">0.86<br/>(0.79, 0.94)</td>
<td align="center" colspan="1" rowspan="1">0.82<br/>(0.75, 0.89)</td>
<td align="center" colspan="1" rowspan="1">0.72<br/>(0.64, 0.81)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">20 mg BID, d 11−17 (n=18)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ ritonavir 100 mg QD/tenofovir 300 mg QD, d 1−10 (am) (n=39), d 11−17 (am) (simultaneous administration with am famotidine) (n=18)<sup>e,f</sup>
</td>
<td align="center" colspan="1" rowspan="1">0.91<br/>(0.84, 0.99)</td>
<td align="center" colspan="1" rowspan="1">0.90<br/>(0.82, 0.98)</td>
<td align="center" colspan="1" rowspan="1">0.81<br/>(0.69, 0.94)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">40 mg QD (pm),<br/>d 18−24 (n=20)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ ritonavir 100 mg QD/tenofovir 300 mg QD, d 1−10 (am) (n=39), d 18−24 (am) (12 h after pm famotidine) (n=20)<sup>f</sup>
</td>
<td align="center" colspan="1" rowspan="1">0.89<br/>(0.81, 0.97)</td>
<td align="center" colspan="1" rowspan="1">0.88<br/>(0.80, 0.96)</td>
<td align="center" colspan="1" rowspan="1">0.77<br/>(0.63, 0.93)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">40 mg BID, d 18−24 (n=18)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD/tenofovir 300 mg QD, d 1−10 (am) (n=39), d 18−24 (am) (10 h after pm famotidine and 2 h before am famotidine) (n=18)<sup>f</sup>
</td>
<td align="center" colspan="1" rowspan="1">0.74<br/>(0.66, 0.84)</td>
<td align="center" colspan="1" rowspan="1">0.79<br/>(0.70, 0.88)</td>
<td align="center" colspan="1" rowspan="1">0.72<br/>(0.63, 0.83)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">40 mg BID, d 11−20 (n=15)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD, d 1−10 (am) (n=46), then 400 mg QD/ritonavir 100 mg QD, d 11−20 (am) (n=15)</td>
<td align="center" colspan="1" rowspan="1">1.02<br/>(0.87, 1.18)</td>
<td align="center" colspan="1" rowspan="1">1.03<br/>(0.86, 1.22)</td>
<td align="center" colspan="1" rowspan="1">0.86<br/>(0.68, 1.08)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">fluconazole</td>
<td align="center" colspan="1" rowspan="1">200 mg QD, d 11−20 (n=29)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ ritonavir 100 mg QD, d 1−10 (n=19), d 11−20 (n=29)</td>
<td align="center" colspan="1" rowspan="1">1.03<br/>(0.95, 1.11)</td>
<td align="center" colspan="1" rowspan="1">1.04<br/>(0.95, 1.13)</td>
<td align="center" colspan="1" rowspan="1">0.98<br/>(0.85, 1.13)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">ketoconazole</td>
<td align="center" colspan="1" rowspan="1">200 mg QD, d 7−13 (n=14)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, d 1−13 (n=14)</td>
<td align="center" colspan="1" rowspan="1">0.99<br/>(0.77, 1.28)</td>
<td align="center" colspan="1" rowspan="1">1.10<br/>(0.89, 1.37)</td>
<td align="center" colspan="1" rowspan="1">1.03<br/>(0.53, 2.01)</td>
</tr>
<tr>
<td valign="top">nevirapine<sup>g,h</sup>
</td>
<td align="center" valign="top">200 mg BID, d 1–23 (n=23)</td>
<td align="center" valign="top">300 mg QD/ritonavir 100 mg QD, d 4–13, then 400 mg QD/ritonavir 100 mg QD, d 14–23 (n=23)<sup>i</sup>
</td>
<td align="center" valign="top">0.72<br/>(0.60, 0.86)<br/>1.02<br/>(0.85, 1.24)</td>
<td align="center" valign="top">0.58<br/>(0.48, 0.71)<br/>0.81<br/>(0.65, 1.02)</td>
<td align="center" valign="top">0.28<br/>(0.20, 0.40)<br/>0.41<br/>(0.27, 0.60)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">omeprazole</td>
<td align="center" colspan="1" rowspan="1">40 mg QD, d 7−12 (n=16)<sup>j</sup>
</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, d 1−6 (n=48), d 7−12 (n=16)</td>
<td align="center" colspan="1" rowspan="1">0.04<br/>(0.04, 0.05)</td>
<td align="center" colspan="1" rowspan="1">0.06<br/>(0.05, 0.07)</td>
<td align="center" colspan="1" rowspan="1">0.05<br/>(0.03, 0.07)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">40 mg QD, d 11−20 (n=15)<sup>j</sup>
</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD, d 1−20 (n=15)</td>
<td align="center" colspan="1" rowspan="1">0.28<br/>(0.24, 0.32)</td>
<td align="center" colspan="1" rowspan="1">0.24<br/>(0.21, 0.27)</td>
<td align="center" colspan="1" rowspan="1">0.22<br/>(0.19, 0.26)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">20 mg QD, d 17−23 (am) (n=13)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD, d 7−16 (pm) (n=27), d 17−23 (pm) (n=13)<sup>k,l</sup>
</td>
<td align="center" colspan="1" rowspan="1">0.61<br/>(0.46, 0.81)</td>
<td align="center" colspan="1" rowspan="1">0.58<br/>(0.44, 0.75)</td>
<td align="center" colspan="1" rowspan="1">0.54<br/>(0.41, 0.71)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">20 mg QD, d 17−23 (am) (n=14)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD, d 7−16 (am) (n=27), then 400 mg QD/ritonavir 100 mg QD, d 17−23 (am) (n=14)<sup>m,n</sup>
</td>
<td align="center" colspan="1" rowspan="1">0.69<br/>(0.58, 0.83)</td>
<td align="center" colspan="1" rowspan="1">0.70<br/>(0.57, 0.86)</td>
<td align="center" colspan="1" rowspan="1">0.69<br/>(0.54, 0.88)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">rifabutin</td>
<td align="center" colspan="1" rowspan="1">150 mg QD, d 15−28 (n=7)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, d 1−28 (n=7)</td>
<td align="center" colspan="1" rowspan="1">1.34<br/>(1.14, 1.59)</td>
<td align="center" colspan="1" rowspan="1">1.15<br/>(0.98, 1.34)</td>
<td align="center" colspan="1" rowspan="1">1.13<br/>(0.68, 1.87)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">rifampin</td>
<td align="center" colspan="1" rowspan="1">600 mg QD, d 17−26 (n=16)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD, d 7−16 (n=48), d 17−26 (n=16)</td>
<td align="center" colspan="1" rowspan="1">0.47<br/>(0.41, 0.53)</td>
<td align="center" colspan="1" rowspan="1">0.28<br/>(0.25, 0.32)</td>
<td align="center" colspan="1" rowspan="1">0.02<br/>(0.02, 0.03)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">ritonavir<sup>o</sup>
</td>
<td align="center" colspan="1" rowspan="1">100 mg QD, d 11−20 (n=28)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD, d 1−20 (n=28)</td>
<td align="center" colspan="1" rowspan="1">1.86<br/>(1.69, 2.05)</td>
<td align="center" colspan="1" rowspan="1">3.38<br/>(3.13, 3.63)</td>
<td align="center" colspan="1" rowspan="1">11.89<br/>(10.23, 13.82)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">tenofovir<sup>p</sup>
</td>
<td align="center" colspan="1" rowspan="1">300 mg QD, d 9−16 (n=34)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, d 2−16 (n=34)</td>
<td align="center" colspan="1" rowspan="1">0.79<br/>(0.73, 0.86)</td>
<td align="center" colspan="1" rowspan="1">0.75<br/>(0.70, 0.81)</td>
<td align="center" colspan="1" rowspan="1">0.60<br/>(0.52, 0.68)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">300 mg QD, d 15−42 (n=10)</td>
<td align="center" colspan="1" rowspan="1">300 mg/ritonavir 100 mg QD, d 1−42 (n=10)</td>
<td align="center" colspan="1" rowspan="1">0.72<sup>q</sup>
<br/>(0.50, 1.05)</td>
<td align="center" colspan="1" rowspan="1">0.75<sup>q </sup>
<br/>(0.58, 0.97)</td>
<td align="center" colspan="1" rowspan="1">0.77<sup>q</sup>
<br/>(0.54, 1.10)</td>
</tr>
</tbody>
</table>